CN116712390A - High-concentration high-stability antibody preparation and preparation method thereof - Google Patents
High-concentration high-stability antibody preparation and preparation method thereof Download PDFInfo
- Publication number
- CN116712390A CN116712390A CN202310976752.0A CN202310976752A CN116712390A CN 116712390 A CN116712390 A CN 116712390A CN 202310976752 A CN202310976752 A CN 202310976752A CN 116712390 A CN116712390 A CN 116712390A
- Authority
- CN
- China
- Prior art keywords
- antibody
- preparation
- histidine
- antibody preparation
- buffer system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 52
- 238000003452 antibody preparation method Methods 0.000 title description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 32
- 239000007853 buffer solution Substances 0.000 claims abstract description 24
- 239000011780 sodium chloride Substances 0.000 claims abstract description 16
- 239000004475 Arginine Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 206010047115 Vasculitis Diseases 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
- 238000010254 subcutaneous injection Methods 0.000 claims description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 206010000234 Abortion spontaneous Diseases 0.000 claims description 3
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 3
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 3
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 3
- 201000005624 HELLP Syndrome Diseases 0.000 claims description 3
- 208000008899 Habitual abortion Diseases 0.000 claims description 3
- 201000004331 Henoch-Schoenlein purpura Diseases 0.000 claims description 3
- 206010019617 Henoch-Schonlein purpura Diseases 0.000 claims description 3
- 208000031814 IgA Vasculitis Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 3
- 208000027032 Renal vascular disease Diseases 0.000 claims description 3
- 206010063837 Reperfusion injury Diseases 0.000 claims description 3
- 201000007023 Thrombotic Thrombocytopenic Purpura Diseases 0.000 claims description 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 3
- 208000002780 macular degeneration Diseases 0.000 claims description 3
- 206010065579 multifocal motor neuropathy Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 208000000995 spontaneous abortion Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 230000009529 traumatic brain injury Effects 0.000 claims description 3
- 208000019553 vascular disease Diseases 0.000 claims description 3
- 206010001526 Air embolism Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 5
- 230000035939 shock Effects 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 206010056489 Coronary artery restenosis Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 abstract description 3
- 239000000872 buffer Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 19
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 17
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 15
- 238000001514 detection method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102100031506 Complement C5 Human genes 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229940125644 antibody drug Drugs 0.000 description 6
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229960003121 arginine Drugs 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- 229960003589 arginine hydrochloride Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 206010018910 Haemolysis Diseases 0.000 description 3
- 206010022822 Intravascular haemolysis Diseases 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 201000001505 hemoglobinuria Diseases 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229960004641 rituximab Drugs 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 208000029713 Catastrophic antiphospholipid syndrome Diseases 0.000 description 2
- 102000004405 Collectins Human genes 0.000 description 2
- 108090000909 Collectins Proteins 0.000 description 2
- 108010028773 Complement C5 Proteins 0.000 description 2
- 101150050927 Fcgrt gene Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000721454 Pemphigus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000024203 complement activation Effects 0.000 description 2
- 229940121394 complement c5 inhibitor Drugs 0.000 description 2
- 239000002720 complement component C5 inhibitor Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007887 coronary angioplasty Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 201000003631 narcolepsy Diseases 0.000 description 2
- 208000017262 paroxysmal cold hemoglobinuria Diseases 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 238000010079 rubber tapping Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037549 Shiga toxin-associated hemolytic uremic syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000032013 atypical susceptibility to 1 hemolytic uremic syndrome Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000004074 complement inhibitor Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229950007085 ravulizumab Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940055944 soliris Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
- 208000017271 typical hemolytic-uremic syndrome Diseases 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a high-concentration high-stability antibody preparation and a preparation method thereof, belonging to the field of antibody preparations, wherein the antibody preparation comprises an anti-C5 antibody, a light chain sequence is SEQ ID NO.1, and a heavy chain sequence is SEQ ID NO.2 or a long-acting modified sequence thereof; also included is a buffer system: 20-50mM histidine-histidine hydrochloride, 70-110mM arginine, 25-50mM sodium chloride and 0.03% PS80. The concentration of the conventional antibody preparation is generally below 100mg/mL, and the concentration of the antibody in the buffer solution system reaches about 200mg/mL. And the antibody preparation of the invention shows good long-term stability, affinity and bioavailability.
Description
Technical Field
The invention belongs to the field of antibody preparations, and particularly relates to a high-concentration high-stability antibody preparation and a preparation method thereof.
Background
With the development of bioantibody drug therapies, high concentrations of the active ingredient (about 20mg/mL to about 100-150mg/mL, even 200mg/mL or higher) are required for intravenous or subcutaneous high concentration administration. In the field of treatment of chronic diseases with a large single dose, such as PNH (paroxysmal sleep hemoglobinuria, which is manifested by chronic intravascular hemolysis), in order to achieve autonomous administration of a patient, to improve convenience and therapeutic compliance of administration of the patient, an antibody preparation with a small administration volume and high concentration needs to be developed. However, antibody drugs can have problems such as increased viscosity, protein aggregation, and altered charge heterogeneity during concentration at high concentrations, which can lead to decreased activity of the active antibody, increased immunogenicity, and the like. Thus, there is a need to improve the formulation of antibody drugs to increase antibody solubility, decrease viscosity, and address the problems of protein aggregation, charge heterogeneity changes.
The improvements to antibody pharmaceutical formulations mainly include the following:
I. antibodies in the formulation;
calcium and acetate or buffer:
the viscosity of the antibody formulation is reduced by adding calcium salts and/or acetate salts (and/or buffers) to the formulation: determination methods the viscosity of the protein formulation is determined before and after addition of calcium salt and/or acetate (and/or buffer);
excipient in formulation:
the excipient can impart or enhance the stability of the protein preparation and influence the efficacy and immunogenicity of the drug to some extent, so that development of the protein preparation of the excipient with stability and safety is required. The excipient may be a buffer, a stabilizer, a surfactant, or the like.
EA5 mab is a humanized monoclonal antibody that specifically targets complement C5. Complement C5 can be converted to C5a and C5b after cleavage, where C5a is an important pro-inflammatory molecule and C5b can continue to form C5b-9, the tapping complex (MAC) that leads to cell perforation or lysis. Deposition of the tapping complex on the surface of erythrocytes in PNH patients can cause erythrocyte lysis, the major clinical manifestation of PNH. EA5 mab blocks C5 cleavage and prevents the formation of C5a and C5b-9 and is therefore useful for the effective treatment of PNH. In addition, the composition has good therapeutic effects on diseases caused by complement end activation, such as aHUS, gMG and the like.
PNH (paroxysmal sleep hemoglobinuria) is a rare and life-threatening hematopoietic stem cell clonal disease with prevalence of about thirteen parts per million, and is clinically manifested mainly by hemolytic anemia, hemoglobinuria, venous thrombosis, bone marrow hematopoietic failure, smooth muscle dysfunction, and the like. Intravascular hemolysis caused by the complement system attacking erythrocytes is a central factor in PNH morbidity and mortality. Ext> CDext> 59ext> isext> theext> mostext> importantext> complementext> complexext> (ext> MACext>)ext> inhibitorext> onext> theext> surfaceext> ofext> erythrocytesext>,ext> andext> PNHext> patientsext> undergoext> acquiredext> somaticext> mutationext> dueext> toext> phosphatidylinositolext> glycanext> (ext> PIGext> -ext> aext>)ext> geneext> locatedext> onext> theext> Xext> chromosomeext> (ext> xpext> 22.1ext>)ext>,ext> resultingext> inext> failureext> ofext> CDext> 59ext> toext> bindext> toext> theext> cellext> membraneext> ofext> erythrocytesext> dueext> toext> theext> defectext> ofext> glycosylext> phosphatidylinositolext> (ext> gpiext>)ext> synthesisext>,ext> andext> eventuallyext> lossext> ofext> functionext> inext> inhibitingext> activationext> ofext> theext> complementext> pathwayext>.ext> The main treatment methods of PNH include complement inhibitors, glucocorticoids, allogeneic hematopoietic stem cell transplantation, etc., wherein complement C5 inhibitors Soliris (Eculizumab) or Ultomiris (Ravulizumab) are standard treatment of PNH, can effectively control intravascular hemolysis, reduce thrombosis and improve long-term survival rate, but the medicines are expensive and need intravenous injection, and patients need regular hospital admission and infusion, thus bringing great inconvenience to life. Therefore, the development of a safe and effective subcutaneous complement C5 inhibitor for treatment of PNH patients is of great significance.
PNH is a disease caused by typical complement activation, EA5 antibody has great therapeutic potential for other diseases caused by complement activation as well, such as rheumatoid arthritis, antiphospholipid antibody syndrome, lupus nephritis, ischemia reperfusion injury, atypical hemolytic uremic syndrome (aHUS), typical hemolytic uremic syndrome, paroxysmal Nocturnal Hemoglobinuria (PNH), compact deposition disease, neuromyelitis optica, multifocal motor neuropathy, multiple sclerosis, macular degeneration, HELLP syndrome, spontaneous abortion, thrombotic thrombocytopenic purpura, oligoimmunovasculitis, epidermolysis bullosa, recurrent abortion, traumatic brain injury, myocarditis, cerebrovascular disorders, peripheral vascular disorders, renal vascular disorders, mesenteric/intestinal vascular disorders, vasculitis, allergic purpura nephritis, systemic lupus erythematosus-associated vasculitis, rheumatoid arthritis-associated vasculitis, immunocomplex vasculitis, high-altitude disease, dilated cardiomyopathy, diabetes mellitus blood vessel, sichuan disease, venous embolism, stent placement, rotational atherectomy, restenosis following percutaneous transluminal coronary angioplasty, myasthenia gravis, collectin's disease, dermatomyositis, paroxysmal cold hemoglobinuria, antiphospholipid syndrome, graves' disease, atherosclerosis, alzheimer's disease, systemic inflammatory response sepsis, septic shock, spinal cord injury, glomerulonephritis, graft rejection, hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, godpasture's syndrome, digoss' disease, and catastrophic antiphospholipid syndrome.
Disclosure of Invention
In order to solve the problems, the invention provides an anti-C5 antibody and a preparation thereof, optimizes the molecular design of the antibody and a buffer system of the preparation, and aims to improve the overall stability of the antibody preparation.
In the present invention, "PS80" refers to polysorbate-80, also known as Tween-80.
In the present invention, "histidine-histidine hydrochloride" refers to histidine sodium histidine hydrochloride+histidine hydrochloride buffer.
In one aspect, the invention provides an anti-C5 antibody.
The anti-C5 antibody is an engineered antibody, the light chain sequence is SEQ ID NO.1, and the heavy chain sequence is SEQ ID NO.2 or a long-acting engineered sequence thereof. The antibody molecule improves the solubility and stability of the antibody by engineering an Fc region; raising the isoelectric point of the antibody to avoid loss of antibody in downstream processes; while increasing the affinity of the antibody for FcRn to achieve a longer in vivo half-life.
Preferably, the long-acting modification sequence of the heavy chain sequence is SEQ ID NO.3.
In another aspect, the invention provides an antibody preparation comprising the foregoing anti-C5 antibody.
The content of the anti-C5 antibody is 0-200mg/L, preferably 160-200mg/mL, and more preferably 180mg/mL.
The antibody preparation also comprises a buffer system.
The buffer system comprises: 20-50mM histidine-histidine hydrochloride, 70-110mM arginine, 25-50mM sodium chloride and 0.03% PS80.
The histidine-histidine hydrochloride content may be selected from: 20-30mM, 30-40mM, 40-50mM, 25-35mM, 25-45mM.
The arginine may be present in an amount selected from: 70-80mM, 80-90mM, 90-100mM, 100-110mM, 70-90mM, 80-100mM, 90-110mM, 100-110mM.
The sodium chloride content may be selected from: 25-30mM, 25-35mM, 30-50mM, 40-50mM, 35-40mM, 25-45mM, 30-45mM.
Preferably, the buffer system comprises: 20mM histidine-histidine hydrochloride, 70-110mM arginine, 25-50mM sodium chloride and 0.03% PS80.
More preferably, the buffer system comprises: 20mM histidine-histidine hydrochloride, 80mM arginine, 25-50mM sodium chloride and 0.03% PS80.
Further preferably, the buffer system comprises: 20mM histidine-histidine hydrochloride, 80mM arginine, 50mM sodium chloride and 0.03% PS80.
The pH of the buffer system is 6.0-6.5.
Preferably, the pH of the buffer system is between 6.0 and 6.3.
Further preferably, the buffer system has a pH of 6.3.
The invention also provides buffer systems for use in antibody formulations.
In a further aspect, the invention provides the use of an anti-C5 antibody or antibody preparation as described above in the manufacture of a medicament.
The pharmaceutical indications are selected from: rheumatoid arthritis, antiphospholipid antibody syndrome, lupus nephritis, ischemia reperfusion injury, atypical hemolytic uremic syndrome (aHUS), atypical hemolytic uremic syndrome, PNH, dense matter deposition disease, neuromyelitis optica, multifocal motor neuropathy, multiple sclerosis, macular degeneration, HELLP syndrome, spontaneous abortion, thrombotic thrombocytopenic purpura, oligoimmunovasculitis, epidermolysis bullosa, recurrent abortion, traumatic brain injury, myocarditis, cerebrovascular disorders, peripheral vascular disorders, renal vascular disorders, mesenteric/intestinal vascular disorders, vasculitis, allergic purpura nephritis, systemic lupus erythematosus-associated vasculitis, rheumatoid arthritis-associated vasculitis, immune complex vasculitis, high-amp disease, dilated cardiomyopathy, diabetic vasculopathy, kawasaki disease, venous air embolism, stent placement, rotational atherectomy, restenosis following percutaneous transluminal coronary angioplasty, myasthenia gravis, collectin's disease, dermatomyositis, paroxysmal cold hemoglobinuria, antiphospholipid syndrome, graves' disease, atherosclerosis, alzheimer's disease, systemic inflammatory response sepsis, septic shock, spinal cord injury, glomerulonephritis, graft rejection, hashimoto's thyroiditis, type I diabetes, psoriasis, pemphigus, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, godpassch's syndrome, digoss' disease, or catastrophic antiphospholipid syndrome.
Preferably, the indication of the medicament is PNH.
In yet another aspect, the invention provides a medicament comprising the foregoing anti-C5 antibody or antibody preparation.
Preferably the medicament is for use in the treatment of PNH.
Preferably, the medicament is in the form of injection.
In yet another aspect, the invention provides the use of the buffer system described above in the preservation of antibody drugs.
Preferably, the antibody drug is an anti-C5 antibody-related drug, such as the preservation of anti-C5 antibodies described above.
The invention has the beneficial effects that:
compared with the prior art, the invention improves the stability of the anti-C5 antibody, improves the related buffer system of the antibody preparation, solves the problems of high viscosity, aggregation, change of charge heterogeneity and the like of the antibody preparation, and improves the stability of the corresponding high-concentration liquid preparation of the antibody. The concentration of the conventional antibody preparation is generally below 100mg/mL, and the concentration of the antibody in the buffer solution system reaches about 200mg/mL. And the antibody preparation of the invention shows good long-term stability, affinity and bioavailability.
Drawings
FIG. 1 shows the inhibitory activity of various concentrations of EA5 antibody on Complement Dependent Cytotoxicity (CDC).
FIG. 2 is a graph of ICR mice given a single intravenous and subcutaneous injection of 30mg/kg of EA5 antibody.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the present invention, but are merely illustrative of the present invention. The experimental methods used in the following examples are not specifically described, but the experimental methods in which specific conditions are not specified in the examples are generally carried out under conventional conditions, and the materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
Example 1 preparation of an anti-C5 antibody preparation
(1) Preparation of antibodies
A highly stable anti-C5 antibody having the heavy chain sequence of SEQ ID No.2: the light chain sequence is SEQ ID NO.1. Long-acting modification is carried out on the heavy chain of the modified antibody to increase half-life, and the heavy chain sequence of the modified antibody is SEQ ID NO.3; the light chain sequence is SEQ ID NO.1.
The preparation method of the antibody of the embodiment is a conventional preparation method in the field, an expression vector is constructed, a high-expression stable cell strain is constructed by transferring into a host cell CHO in a stable rotation mode, batch feed culture is carried out on seed cells, the anti-C5 antibody is expressed, and after the anti-C5 antibody is obtained after the harvesting, the affinity chromatography and the ion exchange chromatography are carried out.
(2) Preparation of buffer
The buffer is prepared according to a specific formula, and the pH of the buffer is adjusted to 6.3.
(3) Preparation of antibody formulations
The modified antibody of step (1) and the buffer of step (2) were used to prepare a high concentration antibody preparation at a concentration of 180mg/mL antibody. The preparation process is as follows:
setting the rotating speed of a centrifugal machine to 3500 rcf, concentrating and replacing protein into a preparation prescription by using an ultrafiltration centrifugal tube, replacing the protein by 155 times, adjusting the protein concentration to 180mg/mL of target concentration, filtering and subpackaging each prescription sample into a 2R penicillin bottle and a5 mL liquid storage bag in an ultra-clean bench, and capping the penicillin bottle by plugging.
Prescription 1 buffer: 50mM histidine-histidine hydrochloride, 80mM arginine hydrochloride, 25 mM sodium chloride, 0.03% (w/v) PS80. The buffer pH was adjusted to 6.3.
Prescription 2 buffer: 20mM histidine-histidine hydrochloride, 80mM arginine hydrochloride, 25 mM sodium chloride, 0.03% (w/v) PS80.
Prescription 3 buffer: 20mM histidine-histidine hydrochloride, 110mM arginine hydrochloride, 25 mM sodium chloride, 0.03% (w/v) PS80.
Prescription 4 buffer: 20mM citric acid-sodium citrate+70 mM arginine hydrochloride+50 mM sodium chloride+0.03% PS80 pH6.3.
Experimental example 1 quality Property study of antibody preparation
Taking prescription 1 as an example, the appearance, protein concentration, osmolarity, viscosity, SEC-HPLC assay, CEX-HPLC, nrCE-SDS, binding activity, affinity to C5 and CDC effect were determined for the antibody preparation.
(1) The method for detecting the protein concentration comprises the following steps: protein content was measured using an ultraviolet spectrophotometer (Shimadzu, model: UV-1900). Extinction coefficient of protein was 1.531 (mg/mL) -1 ·cm -1 . The micro cuvettes are cleaned by ultrapure water for 2-3 times, ultrapure water is respectively added into the two micro cuvettes, 200 mu L/cuvette is used for blank correction, 200 mu L/cuvette sample is added, and the three times of continuous reading are carried out. The concentration of the sample was calculated from the extinction coefficient, dilution and OD value.
(2) The osmotic pressure detection method comprises the following steps: the sample is placed on a sample measuring probe of an osmometer, the instrument automatically starts measuring, and the test result is displayed and printed after 1 minute.
(3) The viscosity detection method comprises the following steps: a microVISC pipettes injector is used for sucking a certain volume of sample, the needle of the injector is propped against a sample inlet, and after the sample is loaded, the instrument automatically starts to measure.
(4) Detection column manufacturer of SEC-HPLC: agilent model advanced bio SEC 300A, specification 2.7 μm.
High performance liquid HPLC manufacturer: thermo, ultiMate 3000.
The mobile phase composition was 20mM PB+200 mM NaCl+100mM Arg,pH6.8.
And integrating by adopting an area normalization method, and calculating a main peak, a polymer peak and a fragment peak after the monomer.
The SEC-HPLC purity detection conditions are specifically as follows:
(5) CEX-HPLC purity
Chromatographic column: manufacturer Sepax, model Proteomix SCX-NP5, specification 4.6X1250 mm; high performance liquid chromatograph HPLC: manufacturer Thermo, model UltiMate 3000. Mobile phase a:20mM MES, pH 6.5; mobile phase B:20mM MES+500mM NaCl,pH 6.5. The results were quantitatively analyzed by peak area normalization, and the acid component content (sum of all peak area percentages before the main peak), the main component content (main peak area percentage) and the alkaline component content (sum of all peak area percentages after the main peak) were calculated. The details are given in the following table:
CEX-HPLC purity detection method
(6) nrCE-SDS purity
Capillary electrophoresis apparatus: manufacturer SCIEX, model PA800 Plus. Capillary electrophoresis chromatograph: manufacturer G7100A, model aglent. Desalting a sample, adding a pH6.5 citric acid-phosphate buffer solution into the sample, centrifuging the sample to 400 mu L at 13000rpm for 15min, reversely inserting the centrifuged concentrated column into a new centrifuge tube, centrifuging at 6000rpm for 3min, recovering protein, adding a 250mM NEM solution, uniformly mixing, heating at 70 ℃ for 10min, cooling, centrifuging at 10000rpm for 3min, and injecting samples. With a PDA detector, the detection window is 100 x 800 μm. The sample is introduced from the left end of the capillary, and the effective separation length of the capillary is 20cm. Voltage injection was used for 20 seconds at 5kV. Constant voltage separation is adopted, and the separation voltage is 15kV. The alkaline wash was forward 70psi for 3min, the acidic wash was forward 70psi for 1min, the pure water was forward 70psi for 1min, and the SDS gel buffer was forward 70psi for 10min. And calculating the content of the high molecular component (the sum of all the area percentages of the peaks before the main peak), the content of the main component (the area percentage of the main peak) and the content of the low molecular component (the sum of all the area percentages of the peaks after the main peak) by adopting a peak area normalization method.
(7) Binding activity detection method (ELISA):
250 μg/mL of C5 antigen (purchased from Acro Bio under the trade designation CO5-H52 Ha) was diluted to 0.5 μg/mL with 1 XPBS coating buffer and 100 μl/well coated with 96-well enzyme label overnight at 4deg.C. Plates were washed 4 times, 250 μl/well of blocking solution was added and incubated for 2 hours at room temperature. The plate was washed 4 times and 100. Mu.L/well of the gradient diluted sample was transferred to a 96 well ELISA plate and incubated at room temperature for 1 h. Washing the plate for 4 times, adding secondary antibody working solution (diluted 1:20000) into 100 mu L/hole, standing at room temperature, and incubating for 1 h. Washing the plate for 4 times, adding TMB color development liquid into 100 mu L/hole, reacting for 10min at room temperature, and adding stop solution. Absorbance at 450 nm was read on a microplate reader at 630 nm as a reference wavelength. OD with concentration on the abscissa 450-630nm Four-parameter curve fitting is performed for the ordinate, and EC can be directly obtained 50 And R is 2 And calculating to obtain the relative binding activity of the sample to be detected. Relative binding Activity = reference (or working reference) EC 50 Sample to be tested EC 50 ×100%。
The main quality attributes are detected as follows:
experimental example 2 affinity detection of antibody preparation
(1) The affinity of the anti-C5 antibody to C5 was detected as follows:
the biotin-labeled C5 was diluted to 5. Mu.g/mL with SD buffer (0.1% BSA,0.01% Tween 20,1 XPBS), the test sample was diluted to 50. Mu.g/mL, triplicate samples were prepared, the diluted test sample, fcRn and SD buffer were added to a black 96-well plate, SA Sensor and black 96-well plate were placed in the instrument, and the program was set for curve fitting and data analysis. The results of the formulation test shown in prescription 1 are as follows:
the results show that the anti-C5 antibodies of the invention have better affinity with C5.
(2) The affinity of the antibody to FcRn was detected as follows:
before the experiment, the pH of SD buffer solution is adjusted to 6.0, the FcRn with biotin mark is diluted to 5 mug/mL by SD buffer solution, then the test sample is diluted to 50 mug/mL, three parts are prepared in parallel, the diluted test sample, fcRn and buffer solution are respectively added into a black 96-well plate, SA Sensor and the black 96-well plate are placed into equipment instrument, and a program is set for curve fitting and data analysis. Eculizumab (see US 6355245, construction of expression plasmid, 293T cells plus PEIUS5736137A were used by transient transfection and buffer was added after one-step affinity chromatography for preservation) as positive control.
The detection results are as follows:
the detection result shows that the binding capacity of the antibody in the antibody preparation provided by the invention to FcRn is superior to that of a positive control.
(3) CDC effects of different concentrations of antibodies were detected. The detection method comprises the following steps:
an appropriate amount of target cells (human Burkitt's lymphoma cells, ATCC CCL-213) was added with 10. Mu.g/mL Rituximab (see U.S. Pat. No.3,182,62A, expression plasmid was constructed, 293t cells were transiently transfected with PEI and used after one-step affinity chromatography with buffer for storage) and incubated for half an hour, antibody drug at a concentration ranging from 216ng/mL to 12500ng/mL was added, incubated for 3 hours, equilibrated to room temperature was removed, cell titer detection reagent (Promega, cat# G7572) was added, and the cells were read after shaking in the dark. Four-parameter curve fitting was performed with antibody drug concentration on the abscissa and RLU value on the ordinate, where RLU value was positively correlated with cell lysis rate. The results are shown in FIG. 1. FIG. 1 shows that as the concentration of antibody becomes lower, the cell lysis rate increases, the complement-induced CDC effect by Rituximab increases, while high concentrations of anti-C5 antibody can inhibit the CDC effect by Rituximab.
Experimental example 3 accelerated stability test
The formulations of the prescribed 1-4 antibodies were left at 40℃for 14 days, and the initial parameters (T0) and 14-day parameters thereof were examined with reference to experimental example 1 to evaluate the stability of the formulations, with the following results:
experimental example 4 subcutaneous injection bioavailability
Taking prescription 1 as an example, the bioavailability of the antibody preparation is studied, and the specific method is as follows: in the experiment, after subcutaneous and intravenous injection of an antibody preparation to a CD-1 mouse, the change of the blood concentration of the antibody in the mouse with time is observed, so that the basic pharmacokinetic parameters of the medicine are obtained, and the basic kinetic characteristics of a test object are known.
The specific method comprises the following steps:
the groups were randomly grouped according to body weight, 6 each, male and female halves. A single tail vein injection or a single subcutaneous neck injection of antibody preparation was performed using ICR mice (8 weeks old, body weight 30 g) at a dose of 10mL/kg.
Sampling time: immediately after the administration (within 1 min), 1 h + -5 min, 6 h + -5 min, 24 h + -5 min, 48 h + -5 min, 72 h + -5 min, 96 h + -5 min, 120 h + -5 min, 168 h + -5 min, 240 h + -5 min, 336 h + -5 min, 504 h + -5 min and 672 h + -5 min; blood collection amount: about 0.2 mL/per time; collecting animals: 3/time point/gender/group; the blood sampling mode is as follows: the orbital veins. The concentration of antibodies in the plasma samples was analytically detected using methodology-verified ELISA assays. All samples were multiplexed. Concentration and time profiles of antibodies in plasma were analyzed by non-compartmental model.
ELISA method for determining antibody content in blood plasma:
goat anti-human polyclonal antibodies (ex Abcam, cat No. Ab 6858) were coated on hydrophobic elisa plates and EA5 content in plasma was measured using the double antibody sandwich method. The results are shown in fig. 2, and fig. 2 shows: compared with intravenous injection, the preparation is mainly absorbed by lymphatic system after subcutaneous injection, the peak time of the medicine is 24 hours, the average Cmax is 240 mug/mL, and the bioavailability is about 70%.
Claims (9)
1. An antibody preparation, comprising an anti-C5 antibody and a buffer system;
the anti-C5 antibody has a light chain sequence of SEQ ID NO.1 and a heavy chain sequence of SEQ ID NO.3;
the buffer system consists of 20-50mM histidine-histidine hydrochloride, 70-110mM arginine, 25-50mM sodium chloride and 0.03% PS 80;
the content of the anti-C5 antibody is 160-200mg/mL.
2. The antibody preparation according to claim 1, characterized in that the buffer system consists of 20mM histidine-histidine hydrochloride, 70-110mM arginine, 25-50mM sodium chloride and 0.03% PS80.
3. The antibody preparation according to claim 2, characterized in that the buffer system consists of 20mM histidine-histidine hydrochloride, 80mM arginine, 25-50mM sodium chloride and 0.03% PS80.
4. The antibody preparation of claim 3, wherein the buffer system consists of 20mM histidine-histidine hydrochloride, 80mM arginine, 50mM sodium chloride and 0.03% PS80.
5. The antibody preparation of claim 4, wherein the buffer system has a pH of 6.0-6.5.
6. The antibody preparation of claim 5, wherein the buffer system has a pH of 6.0-6.3.
7. Use of an antibody preparation according to any one of claims 1-6 for the preparation of a medicament for the treatment of rheumatoid arthritis, antiphospholipid antibody syndrome, lupus nephritis, ischemia reperfusion injury, atypical hemolytic uremic syndrome, PNH, dense matter deposition disease, neuromyelitis optica, multifocal motor neuropathy, multiple sclerosis, macular degeneration, HELLP syndrome, spontaneous abortion, thrombotic thrombocytopenic purpura, oligoimmunovasculitis, epidermolysis bullosa, recurrent abortion, traumatic brain injury, myocarditis, cerebrovascular disorder, peripheral vascular disorder, renal vascular disorder, mesenteric/intestinal vascular disorder, vasculitis, allergic purpura nephritis, systemic lupus erythematosus-associated vasculitis, rheumatoid arthritis-associated vasculitis, immunocomplexitis, gaucher's disease, dilated cardiomyopathy, diabetic vasculiopathy, kawasabi, venous air embolism, stent, rotational atherectomy, post-endo-setting, restenosis, coronary artery restenosis, atherosclerosis, coronary artery injury, vascular shock, multiple sclerosis, atherosclerosis, autoimmune diseases, atherosclerosis, vascular shock, autoimmune diseases, multiple sclerosis, atherosclerosis, autoimmune diseases or multiple sclerosis, atherosclerosis, autoimmune diseases or autoimmune diseases.
8. The use according to claim 7, characterized in that it is a subcutaneous injection of a drug.
9. A subcutaneous injection medicament comprising the antibody formulation of any one of claims 1-6.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310976752.0A CN116712390B (en) | 2023-08-04 | 2023-08-04 | High-concentration high-stability antibody preparation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310976752.0A CN116712390B (en) | 2023-08-04 | 2023-08-04 | High-concentration high-stability antibody preparation and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116712390A true CN116712390A (en) | 2023-09-08 |
CN116712390B CN116712390B (en) | 2023-11-14 |
Family
ID=87875507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310976752.0A Active CN116712390B (en) | 2023-08-04 | 2023-08-04 | High-concentration high-stability antibody preparation and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116712390B (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355245B1 (en) * | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
US20140234712A1 (en) * | 2009-02-25 | 2014-08-21 | Catalyst Power Technologies | Energy Storage Devices Including Support Filaments |
CN106459189A (en) * | 2014-03-07 | 2017-02-22 | 瑞颂医药公司 | Anti-C5 antibodies having improved pharmacokinetics |
US20190085095A1 (en) * | 2016-01-25 | 2019-03-21 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
CN110087683A (en) * | 2016-12-16 | 2019-08-02 | 三星Bioepis股份有限公司 | Stabilized aqueous anti-C5 antibody compositions |
CN111315411A (en) * | 2017-07-27 | 2020-06-19 | 瑞颂医药公司 | High concentration anti-C5 antibody formulations |
CN112210005A (en) * | 2019-07-11 | 2021-01-12 | 京天成生物技术(北京)有限公司 | anti-C5 humanized monoclonal antibody with low immunogenicity and low ADCC/CDC function and application thereof |
KR20220047826A (en) * | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | High concentration of anti-C5 formulation |
-
2023
- 2023-08-04 CN CN202310976752.0A patent/CN116712390B/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6355245B1 (en) * | 1994-05-02 | 2002-03-12 | Alexion Pharmaceuticals, Inc. | C5-specific antibodies for the treatment of inflammatory diseases |
US20140234712A1 (en) * | 2009-02-25 | 2014-08-21 | Catalyst Power Technologies | Energy Storage Devices Including Support Filaments |
CN106459189A (en) * | 2014-03-07 | 2017-02-22 | 瑞颂医药公司 | Anti-C5 antibodies having improved pharmacokinetics |
US20190085095A1 (en) * | 2016-01-25 | 2019-03-21 | Shire Human Genetic Therapies, Inc. | Anti-c5 antibodies with enhanced ph switch |
CN110087683A (en) * | 2016-12-16 | 2019-08-02 | 三星Bioepis股份有限公司 | Stabilized aqueous anti-C5 antibody compositions |
CN111315411A (en) * | 2017-07-27 | 2020-06-19 | 瑞颂医药公司 | High concentration anti-C5 antibody formulations |
CN112210005A (en) * | 2019-07-11 | 2021-01-12 | 京天成生物技术(北京)有限公司 | anti-C5 humanized monoclonal antibody with low immunogenicity and low ADCC/CDC function and application thereof |
KR20220047826A (en) * | 2019-08-16 | 2022-04-19 | 리제너론 파마슈티칼스 인코포레이티드 | High concentration of anti-C5 formulation |
Non-Patent Citations (1)
Title |
---|
JANUS ASBJØRN SCHATZ-JAKOBSEN ET AL.: "Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway", J IMMUNOL, vol. 197, pages 337 - 344, XP055398876, DOI: 10.4049/jimmunol.1600280 * |
Also Published As
Publication number | Publication date |
---|---|
CN116712390B (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7405324B2 (en) | stable liquid pharmaceutical formulations | |
CN116585466A (en) | Formulations containing high concentrations of VEGF receptor fusion proteins | |
EA028520B1 (en) | Etanercept formulations stabilized with meglumine | |
EP3569224B1 (en) | Stable liquid formula | |
EP3991745A1 (en) | Formulations containing anti-cd47/pd-l1 bispecific antibody and preparation method therefor and use thereof | |
CN106913869B (en) | anti-CT L A-4 monoclonal antibody preparation and application thereof | |
CA3133138A1 (en) | Liquid composition comprising antibody of human interleukin-4 receptor alpha | |
CN111228479A (en) | anti-PD-L1 antibody preparation | |
CN113840622A (en) | Stable secukinumab injection and preparation method thereof | |
CN110494164A (en) | A kind of human antibody preparation of targeted therapy TNF-α related disease | |
CN116712390B (en) | High-concentration high-stability antibody preparation and preparation method thereof | |
CN115666613A (en) | Stable high-concentration anti-human IL-5 monoclonal antibody liquid preparation | |
EP3824904A9 (en) | Stable liquid pharmaceutical preparation | |
CN111375057A (en) | Pharmaceutical formulation comprising anti-Her 2 monoclonal antibody | |
CA3157797A1 (en) | Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies | |
CN114984207B (en) | anti-PD-1 nano antibody preparation | |
EP4190310A1 (en) | Stable pharmaceutical preparation | |
CN106620691B (en) | Recombinant fully human anti-CTLA-4 monoclonal antibody preparation and application thereof | |
CN110214019B (en) | Pharmaceutical composition for cultivating hippocampus japonicus peptide and preparation method thereof | |
CN112512562A (en) | CTLA4-Ig fusion protein formulations | |
EP4070817A1 (en) | Liquid preparation containing anti-il-17 antibody | |
JP2020531523A (en) | Highly concentrated low-viscosity MASP-2 inhibitory antibody preparations, kits, and methods of treatment for subjects with atypical hemolytic syndrome | |
CN110302377B (en) | Human antibody preparation for targeted therapy of TNF- α related diseases | |
WO2023202685A1 (en) | Pharmaceutical compositons containing anti-her2 antibody for subcutaneous administration | |
EP4151233A1 (en) | Preparation comprising anti-il-23p19 antibody, preparation method therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |